STAAR Surgical Company (STAA)

STAAR Surgical Company is a healthcare equipment and supplies company listed on NASDAQ as common stock. Through its subsidiaries, the company develops, manufactures, and markets phakic implantable lenses for the eye, along with accessory delivery systems used to place the lenses. Its Implantable Collamer Lens portfolio includes EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL, which are used in refractive surgery for conditions such as myopia, hyperopia, astigmatism, and presbyopia. STAAR Surgical serves ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, distributors, and other eye care professionals. The company sells directly in markets including Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, and also works with representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and other international markets. Incorporated in 1982, STAAR Surgical is headquartered in Lake Forest, California.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-STAA
$28.11
35.0% Upside
Undervalued
$27.90
34.0% Upside
Undervalued
Fair
0.0%
November 4, 2026
277.4x
2.9x
3.1x
1.044 B
919.5 M
3.3%
52.1%
7.1
-175.8%
Valuation • Fair Value

STAAR Surgical Company (NASDAQ-STAA) Fair Value by Valuation Model

Review the available estimates for STAAR Surgical Company (NASDAQ-STAA), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$28.11

Estimated upside of 35.0% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$29.84

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0.85

Classic Ben Graham valuation formula reference.

EPV Fair Value

$14.91

Earnings power value estimate.

Comps Fair Value

$28.57

Comparable-company valuation reference.

Analyst Price Target

$27.90

Analysts imply upside of 34.0%.

How to read these valuation models

Use the 7 available valuation references for STAAR Surgical Company (NASDAQ-STAA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for STAAR Surgical Company (NASDAQ-STAA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

339.6 M

Current operating scale indicator.

Revenue Forecast

334.8 M

Forward revenue estimate.

EBITDA

49.764 M

Current operating profitability reference.

EBITDA Forecast

63.916 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review STAAR Surgical Company (NASDAQ-STAA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for STAAR Surgical Company (NASDAQ-STAA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-1.17

Higher caution zone on this screen.

Altman Z-Score

7.1

Relatively strong balance-sheet zone.

FCF / Net Income

-175.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for STAAR Surgical Company (NASDAQ-STAA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for STAAR Surgical Company (NASDAQ-STAA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 4, 2026

Days to Earnings

47

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for STAAR Surgical Company (NASDAQ-STAA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

STAAR Surgical Company (NASDAQ-STAA) Stock Forecast & Technical Outlook

Review STAAR Surgical Company (NASDAQ-STAA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for STAAR Surgical Company (NASDAQ-STAA) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for STAAR Surgical Company (NASDAQ-STAA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for STAAR Surgical Company (NASDAQ-STAA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for STAAR Surgical Company (NASDAQ-STAA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for STAAR Surgical Company (NASDAQ-STAA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for STAAR Surgical Company (NASDAQ-STAA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, STAAR Surgical Company (NASDAQ-STAA) has a Hold consensus, with 3 buy, 8 hold and 1 sell recommendations in the current data set.

Buy 3
Hold 8
Sell 1
FAQ Fast Investor Answers

STAAR Surgical Company (NASDAQ-STAA) Stock FAQ

Data-supported answers about STAAR Surgical Company (NASDAQ-STAA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$28.11
Estimated upside 35.0%
Valuation Rating
Undervalued
Estimated upside of 35.0%
Analyst Target
$27.90
Implied upside 34.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for STAAR Surgical Company (NASDAQ-STAA) is $28.11. This implies an estimated upside of 35.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 35.0% versus the current market price.

The available analyst price target for STAAR Surgical Company (NASDAQ-STAA) is $27.90. The analyst target implies estimated upside of 34.0%.

The current financial health read for STAAR Surgical Company (NASDAQ-STAA) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for STAAR Surgical Company (NASDAQ-STAA) is November 4, 2026.

The latest available data indicates no current dividend yield for STAAR Surgical Company (NASDAQ-STAA).

The current P/E ratio listed for STAAR Surgical Company (NASDAQ-STAA) is 277.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for STAAR Surgical Company is 1.044 B.

The current enterprise value listed for STAAR Surgical Company is 919.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for STAAR Surgical Company is NASDAQ-STAA, and the stock is listed on NASDAQ.

STAAR Surgical Company (NASDAQ-STAA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for STAAR Surgical Company is 3.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for STAAR Surgical Company is 52.1%. Free float helps investors understand how much of the share base is available for public trading.